Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

44.53 -0.12 (-0.27%)

Streaming Delayed Price Updated: 10:46 AM EST, Feb 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	336,319
Open	44.64
Bid (Size)	44.52 (100)
Ask (Size)	44.55 (900)
Prev. Close	44.65
Today's Range	44.37 - 44.90
52wk Range	29.66 - 44.92
Shares Outstanding	388,132,400
Dividend Yield	1.98%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

3 Mid-Cap Stocks We Keep Off Our Radar

February 05, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Via StockStory

3 Profitable Stocks with Open Questions

January 20, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Via StockStory

Performance

YTD	+14.6%	+14.6%
1 Month	+10.9%	+10.9%
3 Month	+15.5%	+15.5%
6 Month	+23.0%	+23.0%
1 Year	+40.4%	+40.4%

More News

Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

January 20, 2026

From Royalty Pharma plc

Via GlobeNewswire

Why Is TEVA Stock Rising Pre-Market Today? ↗

January 12, 2026

Via Stocktwits

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

January 11, 2026

From Royalty Pharma plc

Via GlobeNewswire

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

January 11, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Royalty Pharma Announces Dividend Increase

January 09, 2026

From Royalty Pharma plc

Via GlobeNewswire

Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)

January 07, 2026

Via StockStory

3 Overrated Stocks We Steer Clear Of

December 31, 2025

Via StockStory

Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones

December 29, 2025

From Royalty Pharma plc

Via GlobeNewswire

3 Healthcare Stocks We’re Skeptical Of

December 16, 2025

Via StockStory

Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million

December 16, 2025

From Royalty Pharma plc

Via GlobeNewswire

What's going on in today's after hours session ↗

December 08, 2025

Via Chartmill

Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shows Strong Technical Setup for a Breakout ↗

December 06, 2025

Via Chartmill

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

December 04, 2025

From Royalty Pharma plc

Via GlobeNewswire

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

December 04, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

3 Mid-Cap Stocks That Concern Us

December 03, 2025

Via StockStory

Royalty Pharma to Present at Upcoming Investor Conferences

November 26, 2025

From Royalty Pharma plc

Via GlobeNewswire

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗

November 18, 2025

Via Investor's Business Daily

3 Value Stocks with Warning Signs

November 17, 2025

Via StockStory

3 Low-Volatility Stocks We Find Risky

November 16, 2025

Via StockStory

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings?

November 12, 2025

Via StockStory

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

Via MarketMinute

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗

November 05, 2025

Via Benzinga

Frequently Asked Questions

Is Royalty Pharma plc - Class A Ordinary Shares publicly traded?

Yes, Royalty Pharma plc - Class A Ordinary Shares is publicly traded.

What exchange does Royalty Pharma plc - Class A Ordinary Shares trade on?

Royalty Pharma plc - Class A Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Royalty Pharma plc - Class A Ordinary Shares?

The ticker symbol for Royalty Pharma plc - Class A Ordinary Shares is RPRX on the Nasdaq Stock Market

What is the current price of Royalty Pharma plc - Class A Ordinary Shares?

The current price of Royalty Pharma plc - Class A Ordinary Shares is 44.53

When was Royalty Pharma plc - Class A Ordinary Shares last traded?

The last trade of Royalty Pharma plc - Class A Ordinary Shares was at 02/09/26 10:46 AM ET

What is the market capitalization of Royalty Pharma plc - Class A Ordinary Shares?

The market capitalization of Royalty Pharma plc - Class A Ordinary Shares is 17.28B

How many shares of Royalty Pharma plc - Class A Ordinary Shares are outstanding?

Royalty Pharma plc - Class A Ordinary Shares has 17B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.